Share Price and Basic Stock Data
Last Updated: November 6, 2025, 4:34 pm
| PEG Ratio | 2.27 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Beryl Drugs Ltd operates within the pharmaceutical industry, with a current market capitalization of ₹11.7 Cr and a share price of ₹23.0. The company has demonstrated variable revenue trends over the past quarters, with sales reported at ₹4.97 Cr in June 2022, peaking at ₹8.19 Cr in December 2022. However, revenue declined to ₹6.09 Cr in March 2023 before rebounding to ₹8.18 Cr in June 2023. The company recorded total sales of ₹26.84 Cr for the fiscal year ending March 2023, slightly declining to ₹26.73 Cr in March 2024, but projected to be at ₹21.15 Cr in March 2025. The trailing twelve months (TTM) sales stand at ₹21.09 Cr. These fluctuations indicate a challenging market environment, possibly influenced by competitive pressures or regulatory changes. Notably, Beryl Drugs’ sales in the latest quarter (June 2025) are expected to be ₹4.83 Cr, reflecting ongoing volatility in revenue generation.
Profitability and Efficiency Metrics
The profitability of Beryl Drugs Ltd highlights both strengths and weaknesses, with a reported net profit of ₹0.23 Cr and a P/E ratio of 50.7. The operating profit margin (OPM) fluctuated significantly, recorded at 11.39% overall, with peaks of 15.74% in June 2024 and lows of 0.62% in March 2024. This inconsistency in OPM suggests varying cost management effectiveness. The company’s return on equity (ROE) stood at 6.30%, while the return on capital employed (ROCE) was reported at 10.2%, indicating moderate efficiency in generating returns from shareholder equity and total capital. Beryl’s interest coverage ratio (ICR) is robust at 10.28x, suggesting that the company comfortably meets its interest obligations. However, the high P/E ratio compared to sector averages may indicate overvaluation, necessitating attention to operational efficiency and profit generation in the upcoming periods.
Balance Sheet Strength and Financial Ratios
Beryl Drugs Ltd maintains a balance sheet with total reserves of ₹4.41 Cr against borrowings of ₹4.07 Cr, indicating a manageable debt-to-equity position. The company’s total assets were reported at ₹15.96 Cr, reflecting a decrease from ₹17.49 Cr in March 2024. The cash conversion cycle (CCC) is reported at 94.23 days, implying moderate efficiency in managing working capital, although it is considerably higher than typical sector metrics. The company’s liquidity appears stable with current liabilities well-covered by its operating income. Beryl’s financial ratios present a mixed picture; while the interest coverage ratio is healthy, the decline in net profit margins over the years, standing at 0.23% for TTM, raises concerns about overall profitability. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may also reflect limited institutional interest in the company.
Shareholding Pattern and Investor Confidence
Beryl Drugs Ltd’s shareholding structure shows that promoters hold 26.38% of the equity, while the public holds a significant 73.62%. This distribution suggests a strong public interest in the company, with the number of shareholders increasing from 6,939 in December 2022 to 7,446 by June 2025. The consistent promoter holding indicates a stable management presence, but the lack of FIIs and DIIs could suggest a perceived risk or uncertainty among institutional investors. The steady increase in public shareholders indicates growing retail investor confidence; however, it may also highlight the need for improved communication regarding company performance and strategy to attract institutional investors. The dividend payout remains at 0.00%, which might deter income-seeking investors, emphasizing the need for strategic capital allocation to enhance shareholder returns.
Outlook, Risks, and Final Insight
The outlook for Beryl Drugs Ltd hinges on its ability to stabilize revenue and enhance profitability. The company faces risks such as fluctuating sales trends, evidenced by the decline from ₹26.84 Cr in March 2023 to projected ₹21.15 Cr in March 2025. Additionally, the variable operating profit margins and the absence of dividend payouts may impact investor sentiment. Strengths include a robust interest coverage ratio and a manageable debt level, which could provide a buffer against operational challenges. The company must focus on improving operational efficiency and expanding its market presence to attract institutional investors. If Beryl can successfully navigate these risks and capitalize on its strengths, it may improve its financial standing and investor appeal in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Beryl Drugs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 143 Cr. | 114 | 247/84.3 | 32.7 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,887 Cr. | 448 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.5 Cr. | 45.2 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.9 Cr. | 24.5 | 29.1/17.0 | 37.4 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,687.39 Cr | 1,189.17 | 56.81 | 197.60 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.97 | 7.90 | 8.19 | 6.09 | 8.18 | 8.09 | 7.66 | 3.21 | 6.29 | 5.64 | 5.40 | 5.22 | 4.83 |
| Expenses | 4.37 | 7.27 | 7.47 | 5.82 | 7.05 | 7.37 | 6.87 | 3.19 | 5.30 | 5.08 | 4.81 | 4.72 | 4.28 |
| Operating Profit | 0.60 | 0.63 | 0.72 | 0.27 | 1.13 | 0.72 | 0.79 | 0.02 | 0.99 | 0.56 | 0.59 | 0.50 | 0.55 |
| OPM % | 12.07% | 7.97% | 8.79% | 4.43% | 13.81% | 8.90% | 10.31% | 0.62% | 15.74% | 9.93% | 10.93% | 9.58% | 11.39% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.13 | 0.11 | 0.12 | 0.06 | 0.12 | 0.10 | 0.11 | 0.13 | 0.21 | 0.12 | 0.12 | 0.08 | 0.10 |
| Depreciation | 0.25 | 0.19 | 0.22 | 0.15 | 0.28 | 0.29 | 0.31 | 0.32 | 0.28 | 0.33 | 0.31 | 0.32 | 0.38 |
| Profit before tax | 0.22 | 0.33 | 0.38 | 0.06 | 0.73 | 0.33 | 0.37 | -0.43 | 0.50 | 0.11 | 0.16 | 0.10 | 0.07 |
| Tax % | 0.00% | -6.06% | 60.53% | -16.67% | 27.40% | 18.18% | 16.22% | -16.28% | 26.00% | 90.91% | 62.50% | -50.00% | 71.43% |
| Net Profit | 0.22 | 0.34 | 0.14 | 0.06 | 0.53 | 0.27 | 0.31 | -0.35 | 0.37 | 0.01 | 0.05 | 0.15 | 0.02 |
| EPS in Rs | 0.43 | 0.67 | 0.28 | 0.12 | 1.05 | 0.53 | 0.61 | -0.69 | 0.73 | 0.02 | 0.10 | 0.30 | 0.04 |
Last Updated: August 19, 2025, 10:25 pm
Below is a detailed analysis of the quarterly data for Beryl Drugs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 4.83 Cr.. The value appears to be declining and may need further review. It has decreased from 5.22 Cr. (Mar 2025) to 4.83 Cr., marking a decrease of 0.39 Cr..
- For Expenses, as of Jun 2025, the value is 4.28 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.72 Cr. (Mar 2025) to 4.28 Cr., marking a decrease of 0.44 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.55 Cr.. The value appears strong and on an upward trend. It has increased from 0.50 Cr. (Mar 2025) to 0.55 Cr., marking an increase of 0.05 Cr..
- For OPM %, as of Jun 2025, the value is 11.39%. The value appears strong and on an upward trend. It has increased from 9.58% (Mar 2025) to 11.39%, marking an increase of 1.81%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.08 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.38 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.32 Cr. (Mar 2025) to 0.38 Cr., marking an increase of 0.06 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.03 Cr..
- For Tax %, as of Jun 2025, the value is 71.43%. The value appears to be increasing, which may not be favorable. It has increased from -50.00% (Mar 2025) to 71.43%, marking an increase of 121.43%.
- For Net Profit, as of Jun 2025, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.15 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.13 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.04. The value appears to be declining and may need further review. It has decreased from 0.30 (Mar 2025) to 0.04, marking a decrease of 0.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:47 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14.54 | 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.73 | 21.15 | 21.09 |
| Expenses | 13.77 | 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.45 | 19.91 | 18.89 |
| Operating Profit | 0.77 | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.28 | 1.24 | 2.20 |
| OPM % | 5.30% | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.53% | 5.86% | 10.43% |
| Other Income | 0.18 | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.40 | 1.41 | 0.00 |
| Interest | 0.20 | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.47 | 0.54 | 0.42 |
| Depreciation | 0.32 | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.25 | 1.34 |
| Profit before tax | 0.43 | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 | 0.86 | 0.44 |
| Tax % | 37.21% | 38.46% | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% | 33.72% | |
| Net Profit | 0.27 | 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.58 | 0.23 |
| EPS in Rs | 0.53 | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 1.14 | 0.46 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -70.37% | 112.50% | -364.71% | 320.00% | -40.40% | -91.53% | 380.00% | -375.00% | 216.67% | 0.00% | -24.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | 182.87% | -477.21% | 684.71% | -360.40% | -51.12% | 471.53% | -755.00% | 591.67% | -216.67% | -24.68% |
Beryl Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 16% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 63% |
| 3 Years: | 42% |
| TTM: | -62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 29% |
| 3 Years: | 35% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 3% |
| 3 Years: | 8% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: September 10, 2025, 3:11 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves | 1.33 | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.41 |
| Borrowings | 1.53 | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.07 |
| Other Liabilities | 1.79 | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 2.39 |
| Total Liabilities | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 |
| Fixed Assets | 2.79 | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 6.20 |
| CWIP | 0.13 | 0.24 | 0.00 | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.73 | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.00 | 0.00 |
| Other Assets | 6.09 | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.76 |
| Total Assets | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 |
Below is a detailed analysis of the balance sheet data for Beryl Drugs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.09 Cr..
- For Reserves, as of Mar 2025, the value is 4.41 Cr.. The value appears strong and on an upward trend. It has increased from 3.83 Cr. (Mar 2024) to 4.41 Cr., marking an increase of 0.58 Cr..
- For Borrowings, as of Mar 2025, the value is 4.07 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.09 Cr. (Mar 2024) to 4.07 Cr., marking a decrease of 1.02 Cr..
- For Other Liabilities, as of Mar 2025, the value is 2.39 Cr.. The value appears to be improving (decreasing). It has decreased from 3.48 Cr. (Mar 2024) to 2.39 Cr., marking a decrease of 1.09 Cr..
- For Total Liabilities, as of Mar 2025, the value is 15.96 Cr.. The value appears to be improving (decreasing). It has decreased from 17.49 Cr. (Mar 2024) to 15.96 Cr., marking a decrease of 1.53 Cr..
- For Fixed Assets, as of Mar 2025, the value is 6.20 Cr.. The value appears strong and on an upward trend. It has increased from 6.17 Cr. (Mar 2024) to 6.20 Cr., marking an increase of 0.03 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 9.76 Cr.. The value appears to be declining and may need further review. It has decreased from 11.32 Cr. (Mar 2024) to 9.76 Cr., marking a decrease of 1.56 Cr..
- For Total Assets, as of Mar 2025, the value is 15.96 Cr.. The value appears to be declining and may need further review. It has decreased from 17.49 Cr. (Mar 2024) to 15.96 Cr., marking a decrease of 1.53 Cr..
Notably, the Reserves (4.41 Cr.) exceed the Borrowings (4.07 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.76 | -0.99 | -1.19 | -1.78 | -0.44 | -2.22 | -4.32 | -3.67 | -4.85 | -2.54 | -2.81 | -2.83 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64.26 | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.51 | 94.23 |
| Inventory Days | 52.84 | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | |||
| Days Payable | 50.59 | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | |||
| Cash Conversion Cycle | 66.51 | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.51 | 94.23 |
| Working Capital Days | 36.90 | 38.35 | 58.44 | 67.31 | 71.89 | -6.55 | 13.99 | 38.76 | 63.52 | 46.51 | 57.90 | 68.00 |
| ROCE % | 8.42% | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.05% | 10.15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 18 | Mar 17 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.96 | 0.00 |
| Diluted EPS (Rs.) | 1.96 | 0.00 |
| PBDIT Margin (%) | 10.56 | 1.89 |
| PBIT Margin (%) | 8.50 | -1.38 |
| PBT Margin (%) | 7.67 | -3.12 |
| Net Profit Margin (%) | 6.21 | -3.59 |
| NP After MI And SOA Margin (%) | 6.21 | -3.59 |
| Interest Coverage Ratio (X) | 10.28 | -0.79 |
| Interest Coverage Ratio (Post Tax) (X) | 8.50 | -1.06 |
After reviewing the key financial ratios for Beryl Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 17) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
- For Diluted EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
- For PBDIT Margin (%), as of Mar 18, the value is 10.56. This value is within the healthy range. It has increased from 1.89 (Mar 17) to 10.56, marking an increase of 8.67.
- For PBIT Margin (%), as of Mar 18, the value is 8.50. This value is below the healthy minimum of 10. It has increased from -1.38 (Mar 17) to 8.50, marking an increase of 9.88.
- For PBT Margin (%), as of Mar 18, the value is 7.67. This value is below the healthy minimum of 10. It has increased from -3.12 (Mar 17) to 7.67, marking an increase of 10.79.
- For Net Profit Margin (%), as of Mar 18, the value is 6.21. This value is within the healthy range. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
- For NP After MI And SOA Margin (%), as of Mar 18, the value is 6.21. This value is below the healthy minimum of 8. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
- For Interest Coverage Ratio (X), as of Mar 18, the value is 10.28. This value is within the healthy range. It has increased from -0.79 (Mar 17) to 10.28, marking an increase of 11.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is 8.50. This value is within the healthy range. It has increased from -1.06 (Mar 17) to 8.50, marking an increase of 9.56.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beryl Drugs Ltd:
- Net Profit Margin: 6.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 51 (Industry average Stock P/E: 47.65)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 133, Kanchan Bagh, Indore Madhya Pradesh 452001 | beryldrugs25@yahoo.com http://www.beryldrugs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Sethi | Chairman & Director |
| Mr. Sanjay Sethi | Managing Director |
| Mr. Abhinav Naik | Independent Director |
| Mrs. Shreya Saraf | Independent Woman Director |
FAQ
What is the intrinsic value of Beryl Drugs Ltd?
Beryl Drugs Ltd's intrinsic value (as of 06 November 2025) is 49.03 which is 112.25% higher the current market price of 23.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 11.7 Cr. market cap, FY2025-2026 high/low of 43.7/17.4, reserves of ₹4.41 Cr, and liabilities of 15.96 Cr.
What is the Market Cap of Beryl Drugs Ltd?
The Market Cap of Beryl Drugs Ltd is 11.7 Cr..
What is the current Stock Price of Beryl Drugs Ltd as on 06 November 2025?
The current stock price of Beryl Drugs Ltd as on 06 November 2025 is 23.1.
What is the High / Low of Beryl Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Beryl Drugs Ltd stocks is 43.7/17.4.
What is the Stock P/E of Beryl Drugs Ltd?
The Stock P/E of Beryl Drugs Ltd is 51.0.
What is the Book Value of Beryl Drugs Ltd?
The Book Value of Beryl Drugs Ltd is 18.7.
What is the Dividend Yield of Beryl Drugs Ltd?
The Dividend Yield of Beryl Drugs Ltd is 0.00 %.
What is the ROCE of Beryl Drugs Ltd?
The ROCE of Beryl Drugs Ltd is 10.2 %.
What is the ROE of Beryl Drugs Ltd?
The ROE of Beryl Drugs Ltd is 6.30 %.
What is the Face Value of Beryl Drugs Ltd?
The Face Value of Beryl Drugs Ltd is 10.0.